What Percent of Blockage Requires a Stent?

No single percentage of coronary artery blockage automatically triggers a stent. The commonly quoted threshold is around 70 percent narrowing for most coronary arteries and 50 percent for the left main artery, but these numbers are starting points for a conversation, not finish lines for a decision. Whether you actually need a stent depends on a web of factors: whether the blockage is restricting blood flow in practice, whether you are having a heart attack right now, how well medications control your symptoms, and where in the coronary tree the narrowing sits. The story behind that simple-sounding question is more layered than most patients realize.

Where the 70 Percent Number Comes From

When cardiologists talk about “percent stenosis,” they mean how much of the artery’s diameter is narrowed by plaque compared with a nearby normal-looking segment. For decades, angiography was the main way to gauge this, and studies established that blockages of roughly 70 percent or more in a major coronary artery were likely to limit blood flow during exertion. The left main coronary artery, which feeds the bulk of the heart’s muscle, gets a lower threshold of about 50 percent because any restriction there puts a larger territory at risk.

But angiography has a well-known limitation: different cardiologists looking at the same image often disagree on the severity. A consensus statement from the Quantitative Cardiovascular Imaging Study Group noted that invasive coronary angiography, while accurate, carries substantial observer-to-observer variability, which quantitative software can improve but not eliminate.¹ So the percent number you hear may already have a margin of error baked in. That alone should make you cautious about treating any single cutoff as gospel.

Why the Percentage Can Be Misleading

A blockage that looks 75 percent narrowed on an angiogram does not necessarily starve the heart muscle of blood. The artery may have remodeled outward to compensate, or collateral blood vessels may have grown to bypass the narrowing. Conversely, a 50 percent blockage in the wrong spot, with diffuse disease upstream, might choke off more flow than its appearance suggests. Fluid-dynamics research shows that the pressure drop across a narrowing depends heavily on the minimum cross-sectional area, not just on how the narrowing looks from the side.² When stenosis becomes severe, pressure drops and wall shear stress can climb dramatically, with computational models showing that a 75 percent area reduction produces pressure drops roughly eight times normal and wall stress peaks about fifteen times higher than in a healthy artery.³

This is why modern cardiology has increasingly moved away from deciding on stents purely by how a blockage looks and toward measuring how it actually behaves.

Fractional Flow Reserve and the Shift to Functional Testing

Fractional flow reserve, or FFR, is a pressure-wire measurement taken during a catheterization. A thin wire is threaded past the blockage, and the pressure downstream is compared with the pressure upstream while the artery is maximally dilated with a drug. The result is a number between 0 and 1. A value above 0.80 means the blockage is not significantly limiting flow, and stenting can safely be deferred. A value of 0.75 or below strongly predicts reduced blood supply to the heart muscle. The range between 0.76 and 0.80 is a gray zone where the clinical picture has to tip the scales.⁴

In practice, FFR often reveals that blockages appearing moderate on angiography are hemodynamically harmless, and occasionally that seemingly modest lesions are flow-limiting. The FAME trials established that guiding stent decisions by FFR rather than by angiographic appearance alone led to fewer unnecessary stents and better outcomes.

A non-invasive cousin of this technique now exists: CT-derived fractional flow reserve, or FFRCT, which models coronary blood flow from a standard CT angiogram. It uses the same thresholds: above 0.80 is normal, 0.76 to 0.80 is borderline, and 0.75 or below is abnormal.⁵ Validation studies have confirmed that FFRCT closely tracks the results of invasive FFR.⁶ This means that for some patients, the question of whether a blockage truly matters can be answered before anyone threads a catheter into a coronary artery at all.

What the Landmark Trials Actually Showed

Two large, well-designed trials reshaped how cardiologists think about stenting in patients with stable coronary disease, meaning people with blockages who are not in the middle of a heart attack.

The COURAGE trial, published in 2007, randomized patients with stable angina and significant blockages to either stenting plus optimal medical therapy or medical therapy alone. Over roughly four and a half years, the rates of death and heart attack were virtually identical: about 19 percent in both groups.⁷ The trial was widely discussed and did lead to a measurable decline in elective stent procedures, though the drop was smaller than many expected.⁸

Then came the ISCHEMIA trial, published in 2020, which enrolled patients with stable coronary disease and at least moderate ischemia on stress testing. Over a median follow-up of about three years, an invasive strategy (stenting or bypass surgery) did not reduce the combined rate of cardiovascular death, heart attack, hospitalization for unstable angina, heart failure, or cardiac arrest compared with medical therapy alone.⁹ From an interventional cardiologist’s perspective, the headline was that invasive management did not reduce overall major adverse cardiac events in the intermediate term, although it did sustainably reduce angina symptoms and lowered the rate of spontaneous (non-procedural) heart attacks.¹⁰

Even in a sub-analysis focused on patients with chronic total occlusions, meaning arteries that were completely blocked, the invasive approach did not clearly reduce death or heart attack, though it did significantly improve angina-related quality of life.¹¹

The takeaway is stark: for stable patients, stents relieve symptoms but have not been shown to prevent heart attacks or extend life compared with aggressive medical therapy. That distinction matters enormously, because many patients walk into the cath lab believing the opposite.

When a Stent Is Clearly Needed

The calculus changes completely during an acute coronary syndrome, especially a heart attack. When a plaque ruptures and a blood clot suddenly blocks an artery, restoring blood flow with an emergency stent is life-saving. Guidelines rate revascularization as clearly appropriate for patients presenting with acute ST-elevation heart attacks, and the evidence supporting urgent stenting in that setting is not in dispute.¹²

For other forms of acute coronary syndrome such as unstable angina and non-ST-elevation heart attacks, the situation is more nuanced but still tilts toward intervention. Data on patients with left main coronary disease treated with drug-eluting stents found a stepwise increase in risk: those with stable disease had the lowest risk of cardiac death and heart attack, patients with unstable angina had intermediate risk, and those presenting with a non-ST-elevation heart attack had the highest risk, with more than double the adjusted hazard of cardiac death or heart attack compared with stable patients over two years.¹³ In emergencies, nobody is debating whether the blockage hits some magic percentage; the priority is reopening the artery.

Left Main Disease and High-Risk Anatomy

The left main coronary artery is the trunk that supplies most of the left ventricle, so blockages there carry outsized risk. A narrowing greater than 50 percent in the left main has traditionally been considered an indication for coronary bypass surgery rather than stenting.¹⁴ However, drug-eluting stents have progressively challenged that default. A large Korean registry comparing stenting with bypass in patients with left main disease found no significant difference in death or the combined rate of death, heart attack, and stroke, though stent recipients were significantly more likely to need a repeat procedure on the same vessel.¹⁵

Gender does not appear to change the fundamental outcomes. A large registry of over 2,300 patients with left main disease treated with drug-eluting stents found that women had different baseline characteristics but similar rates of the primary composite outcome compared with men, though women had a higher raw rate of needing repeat treatment on the same lesion, a difference that disappeared after adjusting for confounders.¹⁶

The decision between stenting and bypass for left main disease depends heavily on the complexity of the blockage and whether other arteries are also involved. Current guidelines use scoring systems to gauge this complexity, and patients with simpler anatomy tend to do well with stents while those with extensive multivessel disease are usually steered toward surgery.

Why Moderate Blockages Cause Heart Attacks

Here is one of the most counterintuitive facts in cardiology: the blockages that cause heart attacks are often not the severe ones. Plaques that rupture and trigger a clot tend to be those with a thin, inflamed cap and a large lipid core, and these “vulnerable” plaques frequently cause only moderate narrowing on an angiogram.¹⁷ A lesion that looks like 40 or 50 percent on the screen can be far more dangerous than a stable, calcified 80 percent lesion that has been there for years.

This is a core reason why stenting severe but stable blockages does not prevent heart attacks in clinical trials. The stent props open one narrowing, but the plaque that will actually rupture next month may be sitting in a completely different spot, looking unremarkable on the angiogram. Medications like statins, blood-pressure drugs, and antiplatelet agents work systemically throughout the arterial tree, which is why they remain the backbone of prevention.

Ischemia Without Obstructive Blockages

Some patients have chest pain, abnormal stress tests, and clear evidence of reduced blood flow to the heart, yet their coronary arteries look open on an angiogram. This condition, known as INOCA (ischemia with non-obstructive coronary arteries), can result from disease in the tiny microvessels that angiography cannot see, coronary artery spasm, myocardial bridging where the artery dips under a band of heart muscle, diffuse low-grade plaque buildup, or some combination.¹⁸ Stents have no role here because there is no focal blockage to prop open. Treatment focuses on medications tailored to the specific mechanism, and the 2024 European Society of Cardiology guidelines formally recognized INOCA as a distinct clinical entity deserving structured workup.

What Patients Often Get Wrong About Stents

A qualitative study exploring patient perspectives found a revealing disconnect. Even when medical records showed the primary purpose of their stent was symptom relief, patients commonly believed the stent was placed to prevent a heart attack, clear a dangerous blockage, or extend their life. Several patients explicitly stated they thought the stent saved them from an imminent heart attack.¹⁹ That belief is understandable given how stents are discussed in popular media, but for stable disease it is not supported by trial evidence.

This matters for shared decision-making. If you believe a stent will prevent a heart attack and your cardiologist knows it will mainly reduce your chest pain, you and your doctor are weighing the procedure’s risks against different perceived benefits. The ACC/AHA appropriate use criteria explicitly try to standardize this: clinical scenarios are scored on a 1-to-9 scale, with 7 to 9 meaning revascularization is appropriate, 1 to 3 meaning it is rarely appropriate, and 4 to 6 meaning the benefit is uncertain.²⁰ A well-informed patient can ask where their specific situation falls on that scale.

Symptom Relief Is Real, and It Matters

Downplaying the symptom benefit would be a mistake. The ISCHEMIA trial showed that patients who received invasive treatment had impressive and sustainable improvements in angina, physical functioning, and quality of life lasting up to four years, though this benefit was concentrated among the roughly two-thirds who had symptoms at baseline and absent in those who had no angina before the procedure.²¹ An earlier trial, RITA-2, found that angioplasty produced significantly greater improvements in physical functioning, vitality, and general health at three months and one year compared with continued medical treatment, though the differences had narrowed by three years.²²

If chest pain is limiting your daily life and medications are not controlling it well enough, a stent remains a reasonable and effective choice. The key is going in with accurate expectations: better symptoms, yes; a longer life or lower heart-attack risk, probably not, based on current evidence. Economic analyses have found that when FFR guides the stent decision in stable disease, the cost per quality-adjusted life-year gained is modest and may become nearly cost-neutral within a few years.²³

In-Stent Restenosis and Long-Term Risks

Stents are not permanent fixes that you can forget about. Even with modern drug-eluting stents, the artery can narrow again inside the stent, a problem called in-stent restenosis. A recent systematic review and meta-analysis put the pooled incidence of drug-eluting stent restenosis at roughly 13 percent.²⁴ Factors that raised the risk included diabetes, longer stents, more stents, disease in the left anterior descending artery, longer lesions, prior heart attack, and having had a previous stent procedure. Better heart-pumping function was protective.

Stent deployment technique matters as well. Imaging studies done inside the artery after stent placement have shown that inadequate expansion is a predictor of bad outcomes. One large study found that when the minimum area inside the stent fell below a certain threshold, the risk of needing another procedure on the same stent roughly doubled and the risk of stent clotting roughly tripled.²⁵ Optimization protocols using intracoronary imaging aim for expansion of at least 90 percent of the reference vessel area to avoid this.²⁶ These details are the operator’s concern, not the patient’s, but they underscore that how well a stent is placed can be as important as whether it was placed at all.

Questions Worth Asking Your Cardiologist

If you have been told you have a significant coronary blockage and a stent has been recommended, a few questions can help you understand the reasoning. Ask whether the blockage has been assessed functionally, with FFR or a stress test, rather than by appearance alone. Ask whether the recommendation is based on symptom relief or on a belief that it will prevent a future heart attack, and what the trial evidence says for your situation. Ask where your clinical scenario falls on the appropriate-use criteria scale. And if your symptoms are mild or well controlled on medication, ask what happens if you defer the procedure and revisit the decision later. For stable disease, deferral guided by FFR has been shown to be safe when the physiology says flow is adequate.

None of this applies if you are in the emergency department with a heart attack. In that scenario, the answer to “what percent of blockage requires a stent” is simple: whatever percent is causing the acute event, open it now. The nuance lives entirely in the elective, stable-disease space, which is where most of the patient confusion, and most of the overuse debate, resides.